Immunotherapy to avoid surgery for endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) for patients with a specific type of endometrial cancer that has a high number of gene mutations (called dMMR or MSI-H). The goal is to shrink or eliminate the tumor so surgery may not be needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have endometrial cancer (not a rare subtype called carcinosarcoma) that is early to advanced stage and can be removed with surgery.
- Your cancer tests positive for a gene repair defect (dMMR or MSI-H).
- You have not had chemotherapy, radiation, targeted therapy, or immunotherapy for any cancer in the last 5 years.
- You are generally healthy and able to take care of yourself (performance status 0 or 1).
- Your blood counts, liver, and kidney function are within acceptable limits based on recent blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies nivolumab (an immune therapy that helps your body recognize cancer) after surgery for endometrial cancer that has mismatch-repair deficiency (MMR-d) or high microsatellite instability (MSI-H). It aims to lower the chance the cancer comes back by treating “leftover risk” after the tumor is removed.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial tests two immunotherapy drugs given before surgery for locally advanced gastric cancer that has a specific genetic marker (MSI-H or dMMR). The goal is to shrink the tumor and improve outcomes before removing it surgically.
This trial tests a new immunotherapy treatment for advanced or recurrent endometrial cancer. It uses your tumor's genetic features to see if the treatment might work better for you.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.